8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Mar 27, 2026·SEC
Pulmatrix, Inc.(PULM)Earnings, Financials & Key Ratios
PULM•NASDAQ
$1.73
Price updated Jul 6, 2026
AboutPulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$5M+46.5%
- Net Income-$5M+46.0%
- EPS (Diluted)-1.41+46.2%
- ROE-80.93%-14.0%
PULM Price & Volume
Pulmatrix, Inc. (PULM) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Absence Signals Critical Liquidity Risk
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity exhaustion
Key Thesis Takeaways
- Pulmatrix faces a precarious outlook characterized by a complete cessation of revenue, with growth metrics hitting -100% year-over-year as of 2025Q4.
- The company's reliance on dwindling cash reserves, which have fallen from $19.2 million in 2023Q4 to $3.3 million in 2026Q1, suggests an urgent need for external financing to sustain clinical operations.
- Investors should monitor the company's ability to secure capital, as the current trajectory of accumulated deficits totaling $303.5 million poses a significant threat to long-term solvency.
Verdict Logic
the company's cash position has plummeted to $3.3 million as of 2026Q1, indicating a high probability of near-term dilutive financing or potential strategic failure.
PULM Growth Metrics
Pulmatrix, Inc. (PULM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM62.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM63.06%
Return on Capital
10 Years-87.68%
5 Years-53.02%
3 Years-58.43%
Last Year-80.61%
PULM Recent Earnings
Pulmatrix, Inc. (PULM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (100%)●Beat Revenue 3/12 qtrs (60%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.32
—
Rev
—
—
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.25
—
Rev
—
—
Q4 2025
Oct 16, 2025Metric
Actual
Est
EPS
$0.24
—
Rev
—
—
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.42
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.32 | — |
| Q1 2026 | Feb 26, 2026 | $0.25 | — |
| Q4 2025 | Oct 16, 2025 | $0.24 | — |
| Q3 2025 | Aug 6, 2025 | $0.42 | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Pulmatrix, Inc. (PULM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.73 | $6.32M | -1.23 | -100% | — | -80.93% | — | |
| $21.82 | $1.61B | 6.61 | 18.52% | 118.91% | 47.59% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $73.15 | $1.43B | -7.52 | -43.89% | -284.18% | -87% | — | |
| $111.54 | $24.18B | -17.40 | 66.73% | -144.44% | -130.11% | — | |
| $86.55 | $12.19B | -7094.26 | 23258.15% | -48.38% | -55.09% | — |
Compare PULM vs Peers
Pulmatrix, Inc. (PULM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PULM SEC Filings & Documents
Pulmatrix, Inc. (PULM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PULM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PULM Frequently Asked Questions
Pulmatrix, Inc. (PULM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Pulmatrix, Inc. growing?
Pulmatrix, Inc. (PULM) saw revenue decline by 100.0% over the past year.
Is PULM profitable?
Pulmatrix, Inc. (PULM) reported a net loss of $4.5M for fiscal year 2025.
Dividend & Returns
What is PULM's return on equity?
Pulmatrix, Inc. (PULM) has a return on equity (ROE) of -80.9%. Negative ROE indicates the company is unprofitable.
What is Pulmatrix, Inc.'s free cash flow?
Pulmatrix, Inc. (PULM) had negative free cash flow of $4.7M in fiscal year 2025, likely due to heavy capital investments.